INGN vs LIN
INGN: Inogen is a respiratory health technology company providing portable and stationary oxygen concentrators designed to improve mobility and quality of life for patients with chronic respiratory conditions. LIN: A global leader in industrial gases and engineering solutions supporting critical processes across virtually every sector of the economy.
Side-by-side fundamentals
| Metric | INGN | LIN | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $5.94 | $481.70 | |
| Market cap | $158M | $222.1B | |
| P/E as of 2026-10-08 | n/a | 31.10 | |
| PEG as of 2026-10-08, 3-year EPS CAGR to FY2025 | n/a | 1.47 | |
| Net margin FY2025, SEC XBRL | -6.5% | +20.3% | LIN higher |
| Gross margin FY2025, SEC XBRL | +44.2% | n/a | |
| Operating margin FY2025, SEC XBRL | -8.7% | +26.3% | LIN higher |
| ROE FY2025, SEC XBRL | -11.8% | +17.4% | LIN higher |
| ROA FY2025, SEC XBRL | -7.6% | +7.9% | LIN higher |
| Debt / equity as of 2026-09-02 | 0.00 | 0.72 | INGN lower |
| Revenue growth (YoY) as of 2026-09-02 | +3.4% | +6.6% | LIN higher |
| Revenue CAGR (3y) SEC XBRL | -2.6% | +0.6% | LIN higher |
| Dividend yield as of 2026-09-03 | n/a | +1.4% | |
| Dividend streak (yrs) SEC XBRL | 0 | 10 | LIN higher |
| Beta as of 2026-09-02 | 0.92 | 0.45 | |
| 1-year return as of 2026-10-08 close | -31.6% | +3.0% | LIN higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.